Gilead Sciences, Inc. GILD announced positive data on breast cancer drug Trodelvy (sacituzumab govitecan-hziy) from the late-stage ASCENT-04/KEYNOTE-D19 study. Data from the phase III ASCENT-04 ...

These findings support the expectation that Trodelvy combined with Keytruda will become the new SOC in PD-L1-positive TNBC, shifting the frontline treatment paradigm from chemoimmunotherapy to ADC ...

By Deena Beasley (Reuters) -Gilead Sciences’ Trodelvy in combination with Merck (NSE: PROR)’s blockbuster immunotherapy Keytruda lowered the risk of an aggressive type of breast cancer ...

Discover the latest advancements in breast cancer treatment at the 24th Annual International Congress, featuring expert ...

Trodelvy is currently approved in more than 50 countries for second-line or later mTNBC patients and in several countries for certain patients with pre-treated HR+/HER2- metastatic breast cancer.

Gilead Sciences’ first quarter performance saw sales remain flat year over year, which did not meet Wall Street’s revenue ...

The ASCENT-03 trial is a phase 3 study assessing the efficacy and safety of sacituzumab govitecan compared with physician’s choice of treatment in patients with previously untreated, locally advanced, ...

The ASCENT-04 trial results showed that Trodelvy, when combined with Keytruda, reduced the risk of disease progression or death by 35% in patients with PD-L1-positive metastatic TNBC. This was ...

Gilead Sciences shows strong Q1 execution, pipeline momentum, and margin upside, led by HIV and PrEP launches. See why GILD stock is a strong buy.

The ASCENT-04 trial results showed that Trodelvy, when combined with Keytruda, reduced the risk of disease progression or death by 35% in patients with PD-L1-positive metastatic TNBC.

Keytruda plus Trodelvy cuts triple-negative breast cancer (TNBC) progression risk by 35%: In the ASCENT-04/KEYNOTE-D19 trial, the combination of Keytruda plus Trodelvy significantly outperformed ...